7月17日，Oruka Therapeutics盘中上涨9.43%，报90.9美元/股，成交额1.19亿美元。
消息面上，UBS此前发布研报指出，ORKA-001下半年数据有望进一步降低其核心管线风险，预计28周PASI100应答率将从16周的约63%提升至70%-80%，优于艾伯维Skyrizi的表现。此外，UBS认为艾伯维计划收购Apogee Therapeutics验证了Oruka所依托的YTE平台价值，首批一年期持久性数据预计于第三季度末或第四季度公布。公司此前已与Halozyme签署微粒药物递送平台授权协议，进一步优化给药方案，叠加4.96亿美元充裕现金储备，市场对其临床推进信心增强。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.